Results 91 to 100 of about 3,260 (145)

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States. [PDF]

Future Oncol
Brown JR, Munir T, Lipsky AH, Challagulla S, Campbell D, Yang K, Fu Q, Aldairy W, Williams R, Tam CS.   +9 more
europepmc   +1 more source

Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System. [PDF]

Case Rep Hematol
D'Amato M, Baratè C, Cervetti G, Caparello M, Ortenzi V, Naccarato AG, Benedetti E, Galimberti S.   +7 more
europepmc   +1 more source

Moraxella nonliquefaciens Keratitis Due to Ocular Surface Disease in a Patient Treated with Zanubrutinib for Mantle Cell Lymphoma

: Zanubrutinib, a second-generation Bruton tyrosine kinase inhibitor used in B-cell malignancies, has a favorable systemic safety profile, whereas its ocular surface effects remain insufficiently defined.
Haggay Avizemer, Ori Stern
core   +1 more source

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

J Cell Mol Med
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc   +1 more source

Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database. [PDF]

Front Med (Lausanne)
Tu J, Wang Z, Zhang J, Xu H, Li Y, Zhang L, Gong J, Zhao L.   +7 more
europepmc   +1 more source

A Case of Pseudo-Richter Transformation Following Zanubrutinib Discontinuation in CLL. [PDF]

Mediterr J Hematol Infect Dis
Laurenti L, Quaranta T, Tomasso A, Stirparo L, Abbate PL, Bakacs A, Cappoli N, Di Napoli A, Efremov D, Bellisario F, Gattei V, Caldarella C, Calcagni ML, Autore F, Innocenti I.   +14 more
europepmc   +1 more source

P109 | A MULTICENTER RETROSPECTIVE ANALYSIS OF ZANUBRUTINIB THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ("PARTENOPE PROJECT"): REPORT FROM THE CAMPANIA NETWORK ON CHRONIC LYMPHOCYTIC LEUKEMIA

Haematologica
Zanubrutinib, a selective second-generation covalent Bruton tyrosine kinase inhibitor approved in various B-cell malignancies, has showed its activity in B-cell chronic lymphocytic leukemia (CLL).
G. D'arena, M. Lucignano, A. Fresa, G.R. Nunziata, F. Graziani, V. Amico, M. Troiano, R. Fontana, C. Giordano, G. Svanera, V. Sammartano   +10 more
doaj  

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia. [PDF]

Future Oncol
Hou JZ, Choksi R, Maglinte GA, Wang X, Rui PA, Suryavanshi M, Allendorf D, Patel T, Dadla A, Fontaine A, Jonglertham P, Aton L, Hagan M, Morere L, Scott J, Williams R, Ermann DA.   +16 more
europepmc   +1 more source

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives. [PDF]

Cancers (Basel)
Robak T, Wolska-Washer A, Robak P.
europepmc   +1 more source

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up. [PDF]

Adv Ther
Shadman M, Munir T, Xu S, Yang K, Mohseninejad L, Guthrie G, Hirata J, Lefebure M, Williams R, Tam CS.   +9 more
europepmc   +1 more source